Bliss GVS Pharma Limited
Bliss GVS Pharma Limited engages in the development, manufacturing and marketing of pharmaceutical formulations in India and internationally. It offers pharma products, including capsules, creams/gels/ointments, dry powder for injections and oral suspensions, effervescent tablets, eye/ear drops, injections, liquid preparations, lotion, lozenges, nasal solutions, oral solids, parenterals, pessarie… Read more
Market Cap & Net Worth: Bliss GVS Pharma Limited (BLISSGVS)
Bliss GVS Pharma Limited (NSE:BLISSGVS) has a market capitalization of $255.38 Million (₹22.12 Billion) as of March 18, 2026. Listed on the NSE stock exchange, this India-based company holds position #18130 globally and #857 in its home market, demonstrating a -2.97% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Bliss GVS Pharma Limited's stock price ₹209.20 by its total outstanding shares 105722592 (105.72 Million).
Bliss GVS Pharma Limited Market Cap History: 2015 to 2026
Bliss GVS Pharma Limited's market capitalization history from 2015 to 2026. Data shows growth from $205.01 Million to $255.38 Million (1.34% CAGR).
Bliss GVS Pharma Limited Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Bliss GVS Pharma Limited's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
0.02x
Bliss GVS Pharma Limited's market cap is 0.02 times its annual revenue
1.01x
Lower than industry averageLatest Price to Earnings (P/E) Ratio
0.24x
Bliss GVS Pharma Limited's market cap is 0.24 times its annual earnings
10.29x
Lower than industry averageWhat These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $182.00 Million | $5.47 Billion | $824.83 Million | 0.03x | 0.22x |
| 2017 | $248.63 Million | $8.00 Billion | $856.11 Million | 0.03x | 0.29x |
| 2018 | $194.61 Million | $3.64 Billion | $587.85 Million | 0.05x | 0.33x |
| 2019 | $179.34 Million | $8.86 Billion | $1.24 Billion | 0.02x | 0.14x |
| 2020 | $241.35 Million | $6.82 Billion | $972.65 Million | 0.04x | 0.25x |
| 2021 | $124.37 Million | $5.69 Billion | $684.91 Million | 0.02x | 0.18x |
| 2022 | $87.42 Million | $7.38 Billion | $150.40 Million | 0.01x | 0.58x |
| 2023 | $151.48 Million | $7.47 Billion | $708.59 Million | 0.02x | 0.21x |
| 2024 | $201.07 Million | $7.66 Billion | $754.54 Million | 0.03x | 0.27x |
| 2025 | $199.46 Million | $8.10 Billion | $842.99 Million | 0.02x | 0.24x |
Competitor Companies of BLISSGVS by Market Capitalization
Companies near Bliss GVS Pharma Limited in the global market cap rankings as of March 18, 2026.
Key companies related to Bliss GVS Pharma Limited by market ranking:
- Zoetis Inc (NYSE:ZTS): Ranked #423 globally with a market cap of $51.97 Billion USD.
- Haleon plc (NYSE:HLN): Ranked #434 globally with a market cap of $49.87 Billion USD.
- Takeda Pharmaceutical Co. Ltd. (PINK:TKPHF): Ranked #455 globally with a market cap of $47.47 Billion USD.
- Jiangsu Hengrui Medicine Co Ltd (SHG:600276): Ranked #719 globally with a market cap of $28.19 Billion USD ( CN¥206.84 Billion CNY).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #423 | Zoetis Inc | NYSE:ZTS | $51.97 Billion | $118.15 |
| #434 | Haleon plc | NYSE:HLN | $49.87 Billion | $10.46 |
| #455 | Takeda Pharmaceutical Co. Ltd. | PINK:TKPHF | $47.47 Billion | $30.07 |
| #719 | Jiangsu Hengrui Medicine Co Ltd | SHG:600276 | $28.19 Billion | CN¥55.11 |
Bliss GVS Pharma Limited Historical Marketcap From 2015 to 2026
Between 2015 and today, Bliss GVS Pharma Limited's market cap moved from $205.01 Million to $ 255.38 Million, with a yearly change of 1.34%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | ₹255.38 Million | +28.04% |
| 2025 | ₹199.46 Million | -0.80% |
| 2024 | ₹201.07 Million | +32.73% |
| 2023 | ₹151.48 Million | +73.28% |
| 2022 | ₹87.42 Million | -29.71% |
| 2021 | ₹124.37 Million | -48.47% |
| 2020 | ₹241.35 Million | +34.58% |
| 2019 | ₹179.34 Million | -7.84% |
| 2018 | ₹194.61 Million | -21.73% |
| 2017 | ₹248.63 Million | +36.61% |
| 2016 | ₹182.00 Million | -11.22% |
| 2015 | ₹205.01 Million | -- |
End of Day Market Cap According to Different Sources
On Mar 17th, 2026 the market cap of Bliss GVS Pharma Limited was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $255.38 Million USD |
| MoneyControl | $255.38 Million USD |
| MarketWatch | $255.38 Million USD |
| marketcap.company | $255.38 Million USD |
| Reuters | $255.38 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.